American Shared Hospital Services(US:AMS)2025-04-04 19:22Financial Data and Key Metrics Changes - For fiscal year 2024, total revenue increased by 32.9% to $28.34 million compared to fiscal year 2023 [2] - Adjusted EBITDA for fiscal year 2024 increased by 8.9% to $8.9 million [2][18] - In Q4 2024, total revenue rose by 59.2% to $9.1 million compared to Q4 2023 [18] - Net income for fiscal year 2024 increased by 258% to $2.2 million, or $0.33 per diluted share [17] Business Line Data and Key Metrics Changes - Revenue from direct patient services segment for fiscal year 2024 was $12.6 million, a 253% increase from $3.4 million in fiscal year 2023 [13][14] - Revenue from the equipment leasing segment decreased by 15.6% to $17.8 million in fiscal year 2024 [14] - Gamma Knife revenue decreased by 11.6% to $9.7 million for fiscal year 2024 [14] - Proton beam therapy revenue decreased by 1.8% to $10 million in fiscal year 2024 [15] Market Data and Key Metrics Changes - The company has established its first direct patient services cancer treatment centers in the U.S. with the acquisition of three centers in Rhode Island [11] - The international business segment is expected to see continued growth, particularly in Ecuador and the newly opened center in Puebla, Mexico [9][10] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model [1] - Strategic initiatives include expanding the business footprint in Rhode Island and establishing new treatment centers in Mexico [10][11] - The company aims to enhance operational efficiencies and improve patient care through partnerships with local health systems [7][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy and the ability to navigate industry challenges [39][40] - The company anticipates stronger international growth and increased treatment volumes from new facilities [10][12] - Management highlighted the importance of operational efficiencies and technology investments to support growth initiatives [16][39] Other Important Information - The company ended the year with cash and cash equivalents of $11.3 million, down from $13.8 million at the end of 2023 [25] - Shareholders' equity increased to $25.2 million, or $3.92 per outstanding share, compared to $22.6 million, or $3.59 per outstanding share, at the end of 2023 [25] Q&A Session Summary Question: Benefits of expanding footprint in Rhode Island - Analyst inquired about additional benefits from expanding the footprint in Rhode Island and potential economies of scale with new facilities [30] Response: Synergies from partnerships - Management confirmed that there will be synergies from the relationship with Brown University Health and other local health systems, enhancing cancer care provision in the state [32]